1. Stocks
    2. /
  2. Imugene Limited (ASX: IMU)
    3. /

Imugene Limited (ASX: IMU) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Imugene Limited Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Imugene Limited (ASX: IMU)
    Latest News

    Share Market News

    Here are the top 10 ASX shares today

    | Mitchell Lawler

    Here are your top 10 biggest gainers in the ASX 200 on Tuesday.

    Read more »

    A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
    Healthcare Shares

    Imugene (ASX:IMU) share price backtracks 7% despite milestone update

    | Aaron Teboneras

    The company has further expanded its intellectual property portfolio.

    Read more »

    A person with a round-mouthed expression clutches a device screen and looks shocked and surprised.
    Share Gainers

    These are the 5 best performing ASX shares of 2021

    | Brooke Cooper

    The top performing All Ords share of 2021 gained a whopping 659%.

    Read more »

    A doctor shrugs and holds his hands out.
    Share Market News

    Why did Pro Medicus (ASX:PME) and 2 other ASX 200 healthcare shares fall today?

    | Alice de Bruin

    It's been a tough day on the market for healthcare shares.

    Read more »

    A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital
    Healthcare Shares

    Why is the Imugene (ASX:IMU) share price up 8% today?

    | Alice de Bruin

    Shares in the biotech company are on the rise. We take a closer look

    Read more »

    rising medical asx share price represented by excited doctors dancing in ward
    Healthcare Shares

    Here are the 5 best performing ASX biotech shares of 2021

    | Zach Bristow

    It was a rollercoaster year on the ASX for the biotechnology sector. We take a look at the top performers

    Read more »

    An office worker and his desk covered in yellow post-it notes
    Share Market News

    Here are the 3 most heavily traded ASX 200 shares this Tuesday

    | Sebastian Bowen

    Here are the ASX 200 shares dominating trading volumes today.

    Read more »

    An older woman clasps her hands with joy, smiling at the news on her computer as she sits at her kitchen bench..
    Healthcare Shares

    Why the Imugene (ASX:IMU) share price is charging higher today

    | James Mickleboro

    The Imugene share price is rising this morning...

    Read more »

    Share Market News

    Here are the top 10 ASX shares today

    | Mitchell Lawler

    Here are your top 10 biggest gainers in the ASX 200 on Thursday.

    Read more »

    share price rise
    Share Gainers

    Why Bank of Queensland, Imugene, Webjet, and Zip shares are pushing higher

    | James Mickleboro

    These ASX shares are on form today...

    Read more »

    four excited doctors with their hands in the air
    Healthcare Shares

    Imugene share price (ASX:IMU) pops 5% in cancer trial update

    | Monica O'Shea

    Why is this cancer therapy company impressing investors today?

    Read more »

    Graph showing a fall in share price.
    Healthcare Shares

    Why is the Imugene (ASX:IMU) share price falling today?

    | Zach Bristow

    The biopharma company share price is in the red.

    Read more »

    Frequently Asked Questions

    Imugene does not pay dividends at this stage. 

    Imugene Ltd (ASX: IMU) listed on the ASX on 24 November 1993.

    IMU ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Imugene Limited

    Imugene Ltd (ASX: IMU) is a biotechnology company working in cancer immunotherapy.

    The company specialises in clinical-stage immuno-oncology therapies. Its product pipeline includes Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard-care drugs and immunotherapies.

    The company's lead product is HER-Vaxx, a proprietary cancer vaccine for the treatment of gastric and breast cancer, where the cancer is HER-2 positive. The vaccine has demonstrated it stimulates a polyclonal antibody response to HER2/neu. 

    Imugene's various immunotherapy products are involved in ongoing clinical trials involving cancer specialists and researchers worldwide.

    Profile

    since

    Note